Table 2.
Individual Patient Characteristics and Outcomes
| Pt # |
Histology | Age | KPS | Prior Regimens |
Status at HCT |
Donor Type |
GVHD Prophylaxis | aGVHD Grade |
cGVHD Grade |
Relapse/Prog Day post-HCT |
Cause of Death Day post-HCT |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CTCL | 32 | 80 | 7 | IF | MUD | Siro/Tacro/MTX | Grade II | Extensive | Relapse: d 72 | Prog: d 213 |
| 2 | CTCL | 35 | 60 | 8 | IF | MUD | CSA/MMF/MTX | none | NA | Infection: d 34 | |
| 3 | CTCL | 35 | 80 | 4 | IF | MUD | CSA/MMF/ATG | Grade IV | NA | Infection: d 91 | |
| 4 | CTCL | 50 | 80 | 4 | IF | MUD | CSA/MMF | Grade II | Extensive | ||
| 5 | CTCL | 50 | 90 | 6 | CR1 | MUD | CSA/MMF/MTX | none | None | ||
| 6 | CTCL | 50 | 90 | 4 | PR1 | SIB | Siro/Tacro | none | None | ||
| 7 | CTCL | 53 | 70 | 4 | IF | SIB | Siro/Tacro | none | Extensive | ||
| 8 | CTCL | 55 | 80 | 9 | IF | SIB | Siro/Tacro | Grade IV | NA | Prog: d 48 | Infection: d 67 |
| 9 | CTCL | 56 | 90 | 8 | R1 | SIB | Siro/Tacro | none | Extensive | Relapse: d 147 | Prog: d 238 |
| 10 | CTCL | 59 | 80 | 6 | IF | SIB | CSA/MMF | none. | Extensive | Infection d 3165 | |
| 11 | CTCL | 61 | 80 | 4 | IF | SIB | Siro/Tacro | Grade IV | NA | aGVHD: d 71 | |
| 12 | PTCL-NOS | 32 | 80 | 4 | R1 | SIB | Siro/Tacro | none | None | Prog: d 129 | Prog: d 370 |
| 13 | PTCL-NOS | 52 | 95 | 3/auto* | CR2 | SIB | CSA/MMF | none | Extensive | ||
| 14 | PTCL-NOS | 53 | 90 | 2 | CR2 | SIB | Siro/Tacro | none | Limited | ||
| 15 | PTCL-NOS | 57 | 100 | 4 | R1 | MUD | Siro/Tacro/MTX | Grade II | Extensive | ||
| 16 | PTCL/CD8+ | 61 | 100 | 5 | IF | MUD | Siro/Tacro/MTX | Grade II | Limited | ||
| 17 | NK-T cell | 19 | 100 | 2 | R1 | MUD | CSA/MMF/MTX | Grade I | Limited | Infection: d 655 | |
| 18 | NK/T cell | 23 | 70 | 3 | CR2 | MUD | Siro/Tacro | none. | Extensive | Relapse: d 62 | Prog: d 293 |
| 19 | NK-T cell | 24 | 90 | 3 | IF | SIB | Siro/Tacro | none | NA | Prog: d 27 | Prog: d 30 |
| 20 | NK-T cell | 32 | 80 | 1 | PR1 | SIB | Siro/Tacro | Grade 2 | Extensive | Relapse: d 235 | Alive – 5 yrs |
| 21 | NK-T cell | 38 | 100 | 3 | CR2 | SIB | Siro/Tacro | none | Extensive | Infection: d 832 | |
| 22 | AILD | 60 | 80 | 2 | PR1 | MUD | Siro/Tacro/MTX | Grade I | Extensive | ||
| 23 | AILD | 61 | 100 | 4 | IF | MUD | Siro/Tacro/MTX/ATG | Grade I | Extensive | ||
| 24 | AILD | 68 | 95 | 6 | IF | SIB | Siro/Tacro | none | Extensive | ||
| 25 | ALCL/ALK+ | 20 | 80 | 2 | CR2 | MUD | CSA/MMF/MTX | none | Extensive | cGVHD: d 152 | |
| 26 | ALCL/ALK+ | 57 | 100 | 3 | PR1 | SIB | CSA/MMF | Grade I | Extensive | Relapse: d 279 | Alive - 7 yrs |
| 27 | sub panniculitis | 40 | 60 | 8 | IF | SIB | Siro/MMF | Grade IV | NA | Infection: d 57 |
*
includes autologous transplant, KPS – Karnofsky Performance Status score (defined Schag. 1984),CR - complete remission, PR – partial remission, R – relapse, IF – induction failure, PP – primary progressive, MUD – matched unrelated donor, SIB – sibling donor, CSA – cyclosporine, MMF – mycophenylate mofetil,, MTX – methotrexate, SIR – sirolimus, TAC – tacrolimus, ATG – anti-thymocyte globulin, rd = relapse day, dd = death day